WEX Pharmaceuticals Inc. (“WEX”) is a phase II /III clinical stage biopharmaceutical company committed to developing a new class of non-opioid analgesics. WEX’s proprietary platform and the lead product is Halneuron®. The active pharmaceutical ingredient in Halneuron is Tetrodotoxin (TTX) is a sodium channel blocker known to have analgesic effects with clinical signs of efficacy.
Halneuron is in late-stage clinical development for the treatment of moderate-to-severe chemotherapy-induced neuropathic pain, which is a high unmet medical need.

We are a science-driven company committed to putting patients first. Our goal is to provide access to our investigational therapies at the appropriate time and in the correct manner for patients.
Clinical trials and the subsequent timely generation of safety and efficacy data are the most effective way of ensuring review and decision making by Regulatory Authorities. This ultimately has resulted in access to new, safe and effective approved medicines for all patients.

Expanded access Compassionate Use refers to the use of an investigational therapy outside a clinical trial when the primary purpose is to diagnose, prevent, or treat a serious condition in a patient. We understand the need for expanded access programs, and we recognize the importance of having an appropriate policy.